Vulvar Cancer Market Report 2026

The vulvar cancer market size has grown strongly in recent years. It will grow from $0.62 billion in 2025 to $0.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased awareness of gynecologic cancers, availability of surgical oncology expertise, expansion of hospital oncology departments, adoption of radiation therapy techniques, improvements in pathology diagnostics.

The vulvar cancer market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing investments in precision oncology, rising adoption of biologic and immunotherapies, expansion of HPV vaccination impact monitoring, increasing focus on personalized treatment planning, advancements in diagnostic imaging technologies. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of minimally invasive surgical procedures, growing focus on early diagnosis and screening, expansion of multimodal treatment approaches, enhanced integration of personalized oncology care.

The increasing investments in oncology research and medicine are expected to drive the growth of the vulvar cancer market in the coming years. Investments in oncology research and medicine refer to financial resources allocated by governments, pharmaceutical companies, research institutions, and private investors to advance the understanding, prevention, diagnosis, and treatment of cancer. The rise in these investments is attributed to the growing global cancer burden, advancements in precision medicine, increasing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. Such investments support vulvar cancer management by promoting early diagnosis, enhancing treatment options including targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving cancer care infrastructure, and fostering innovative research to better understand disease biology and progression. For example, in May 2024, according to IQVIA, an India-based information technology company specializing in advanced analytics, global spending on cancer medicine reached $223 billion in 2023, a $25 billion increase from 2022, and is projected to rise to $409 billion by 2028. Therefore, the increasing investments in oncology research and medicine are driving the growth of the vulvar cancer market.

The growing emphasis on personalized medicine is also expected to propel the growth of the vulvar cancer market. Personalized medicine involves tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors. Its adoption is increasing to enhance treatment effectiveness and reduce adverse effects by addressing individual patient variability. Personalized medicine supports vulvar cancer management by customizing therapies according to a patient’s genetic profile, improving treatment outcomes while minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. Consequently, the growing focus on personalized medicine is driving the vulvar cancer market.

Key companies in the vulvar cancer market are concentrating on innovations in cancer therapy, such as alpha-radiation cancer therapy, to improve treatment efficacy and patient outcomes. Alpha-radiation cancer therapy delivers targeted alpha particles to tumor cells, causing localized damage to cancerous tissue while minimizing harm to surrounding healthy tissue. For example, in May 2023, Alpha Tau Medical Ltd., an Israel-based company, announced the first use of its Alpha DaRT alpha-radiation therapy for treating squamous cell carcinoma of the vulva. The study, conducted at Addenbrooke’s Hospital within the Cambridge University Hospitals NHS Foundation Trust, plans to recruit 10 participants to assess the safety and efficacy of the therapy. Alpha DaRT offers a targeted, minimally invasive approach, highlighting its potential as a non-surgical treatment option for vulvar cancer.

Major companies operating in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck And Co., Bristol‑Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Intuitive Surgical Operations Inc., Elekta AB, Accuray Incorporated, Xencor, ISA Pharmaceuticals BV, Alpha Tau Medical Ltd, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc, Eli Lilly and Company, AbbVie Inc, Astellas Pharma Inc, Takeda Pharmaceutical Company Ltd, Bayer AG, Ipsen, Gilead Sciences Inc.

North America was the largest region in the vulvar cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vulvar cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vulvar cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vulvar cancer market by increasing costs of imported oncology drugs, radiotherapy equipment, surgical instruments, and diagnostic imaging systems. Cancer treatment centers in North America and Europe are most affected due to dependence on imported pharmaceuticals and high-end medical devices, while Asia-Pacific faces cost pressures in scaling advanced oncology infrastructure. These tariffs can increase treatment expenses and delay technology upgrades. However, they are also encouraging domestic drug manufacturing, local equipment assembly, and regional oncology research investments that strengthen long-term healthcare resilience.

The vulvar cancer market research report is one of a series of new reports that provides vulvar cancer market statistics, including vulvar cancer industry global market size, regional shares, competitors with a vulvar cancer market share, detailed vulvar cancer market segments, market trends and opportunities, and any further data you may need to thrive in the vulvar cancer industry. This vulvar cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vulvar cancer is a type of cancer that develops in the vulva, the external portion of the female genitalia. It usually originates in the skin or tissues of the vulva and can affect the labia, clitoris, or vaginal opening. The most common form is squamous cell carcinoma, which is often associated with human papillomavirus (HPV) infection. Symptoms may include itching, pain, and visible growths or sores on the vulva.

The primary types of vulvar cancer include vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, and basal cell carcinoma. Vulvar squamous cell carcinoma (SCC) begins in the squamous cells of the vulva, the outer part of the female genitalia. Treatment options include chemotherapy, surgery, laser surgery, excision, skinning vulvectomy, radical vulvectomy, radiation therapy, and biologic therapy. These treatments are distributed through both online and offline channels and are utilized by various end users, including hospitals, clinics, research centers, academic institutes, and others.

The vulvar cancer market consists of revenues earned by entities by providing services such as diagnostic testing, clinical consultations, immunotherapy, targeted therapy, and post-treatment care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvar cancer market also includes sales of pharmaceuticals, immunotherapy drugs, targeted therapy medications, diagnostic kits, and medical devices for tumor detection and monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.